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Exosomes are physiologically secreted nanoparticles recently established as natural
delivery systems involved in cell-to-cell communication and content exchange. Due
to their inherent targeting potential, exosomes are currently being harnessed for the
development of anti-cancer therapeutics. Clinical trials evaluating their effectiveness
are demonstrating safety and promising outcomes. However, challenging large-
scale production, isolation, modification and purification of exosomes are current
limitations for the use of naturally occurring exosomes in the clinic. Exosome mimetics
hold the promise to improve the delivery of bioactive molecules with therapeutic
efficacy, while achieving scalability and increasing bioavailability. In this study, we
propose the development of Immune Derived Exosome Mimetics (IDEM) as a scalable
approach to target and defeat ovarian cancer cells. IDEM were fabricated from
monocytic cells by combining sequential filtration steps through filter membranes with
different porosity and size exclusion chromatography columns. The physiochemical
and molecular characteristics of IDEM were compared to those of natural exosomes
(EXO). Nanoparticle Tracking Analysis confirmed a 2.48-fold increase in the IDEM
production yields compared to EXO, with similar exosomal markers profiles (CD81,
CD63) as demonstrated by flow cytometry and ELISA. To exploit the prospective
of IDEM to deliver chemotherapeutics, doxorubicin (DOXO) was used as a model
drug. IDEM showed higher encapsulation efficiency and drug release over time
compared to EXO. The uptake of both formulations by SKOV-3 ovarian cancer cells
was assessed by confocal microscopy and flow cytometry, showing an incremental
drug uptake over time. The analysis of the cytotoxic and apoptotic effect of DOXO-
loaded nanoparticles both in 2D and 3D culture systems proved IDEM as a more
efficient system as compared to free DOXO, unraveling the advantage of IDEM in
reducing side-effects while increasing cytotoxicity of targeted cells, by delivering smaller
amount of the chemotherapeutic agent. The high yields of IDEM obtained compared
to natural exosomes together with the time-effectiveness and reproducibility of their
production method make this approach potentially exploitable for clinical applications.
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Most importantly, the appreciable cytotoxic effect observed on ovarian cancer in vitro
systems sets the ground for the development of compelling nanotherapeutic candidates
for the treatment of this malady and will be further evaluated.
Keywords: exosomes, ovarian cancer, mimetics, immune system, synthetic
INTRODUCTION
Exosomes (EXO) are well established throughout the
scientific community as paramount mediators of cell-to-cell
communication and content exchange (Tkach and Théry,
2016). They mediate physiological processes but have also
been associated with many different pathologies, due to their
capacities of transporting different types of cargos (mainly
RNAs, DNA, lipids and proteins). The molecular composition
and function of exosomes resemble those of their parental cells,
with inherent targeting mechanisms and a lipophilic core that
compartmentalizes native materials (Record et al., 2014) and
provides structural stability to the cargo (De Toro et al., 2015;
Isola and Chen, 2016; Keerthikumar et al., 2016).
Currently, a lot of effort is being put into the development of
approaches capable of effectively harnessing exosomes properties
(i.e., size, molecular content, low immunogenicity) for their
clinical application in the treatment or diagnosis of a plethora
of diseases, including cancer. So far, exosomes have been used
as diagnostic tools due to their molecular content (Tanaka
et al., 2013; Wang et al., 2014) or as therapeutic options,
as in the case of clinical grade exosomes produced to tackle
pancreatic cancer (Mendt et al., 2018) or melanoma in the
form of vaccines (Escudier et al., 2005). The exploitation of
exosomes with different origin as reconfigurable delivery vehicles
also offers opportunities compared to other nanoscopic drug
delivery systems such as liposomes and polymeric nanoparticles
(Conlan et al., 2017). Exosomes are non-immunogenic in nature
due to similar composition as the body’s own cells and can be
loaded with therapeutic moieties, as showed for some cancer
applications. For example, macrophage-derived exosomes were
loaded with the chemotherapeutic agent doxorubicin (DOXO)
and showed the highest cytotoxicity in a pancreatic cancer
model when compared to DOXO-loaded pancreatic cancer cell-
and pancreatic stellate cell-derived exosomes, suggesting that
donor cell-specific differences could influence their utility as drug
delivery vectors (Kanchanapally et al., 2019).
However, regardless of their well-established characteristics
and potential, the use of exosomes for clinical application is
still encountering limitations due to some intrinsic drawbacks
in their production and scalability. The low extraction yields,
as well as the inadequate loading and encapsulation efficiencies
represent some issues for the clinical scalability of this platform,
including their use as drug delivery systems (Ha et al., 2016;
Akuma et al., 2019). Other disadvantages are related to the
different methods used for their isolation, such as low recovery
and purity, high reagent costs, lack of protocol standardization,
morphology and phenotype changes across different techniques
(Li et al., 2019). The current alternatives to exosomes involve
some well-established liposome-based platforms, which already
are or will be heading toward a clinical application, with pegylated
liposomal doxorubicin being the first to be used as a standard
of care in the treatment of cancers such as ovarian, breast and
melanoma (Bobo et al., 2016).
Due to the aforementioned exosomes limitations, a drive
toward a synthetic or semi-synthetic approach to exosomes
has also gained momentum, and some researchers have
demonstrated high yields of production and purity (Conlan et al.,
2017). As an example, Goh et al. (2017a,b) proposed a biomimetic
cell-derived platform obtained after shearing immune cells (U937
cell line) through sequential filtering, and obtained high yields
of doxorubicin encapsulation that were tested on preclinical
models of colon adenocarcinoma. Similar results were obtained
using other cell types, such as macrophages (Raw264.7 cell line)
and embryonic stem cells, to produce mimetic nanoparticles
with a cytotoxic effect on malignant cancer models (Jang et al.,
2013; Jo et al., 2014). In particular, Jang et al. demonstrated
that membrane-derived nanovesicles are efficient for the targeted
delivery of chemotherapeutics both in vitro and in vivo, regardless
of whether they are produced naturally or artificially from cells
(Jang et al., 2013).
Among the different tumors semi-synthetic and biomimetic
platforms have been applied to, to the best of our knowledge
no such approach has been developed or tested for the
treatment of ovarian cancer. Ovarian cancer is the most lethal
gynecological malignancy (Siegel et al., 2020) and responds
poorly to the standard therapies and to immunotherapies
(Ghisoni et al., 2019). Several efforts are currently ongoing to
exploit the potential of nanomedicine, immunotherapy or even
a combination of the two to better treat ovarian cancer patients
(Corradetti et al., 2019). In particular, there is an urgent need
for the development of therapeutic strategies able to exploit the
physical and biological barriers present in the peritoneal cavity
of metastatic ovarian cancer in order to precisely accumulate
at the disease site (Nizzero et al., 2020). Due to their capacity
to stimulate the immune system and to act as chemoattractants
for other cell populations, exosomes derived from immune cells
represent ideal candidates to boost an anti-cancer response in
immunologically cold tumors such as ovarian cancer.
Here, we demonstrate the development of Immune Derived
Exosome Mimetics (IDEM) as a scalable approach to target
ovarian cancer cells. By subjecting cells to serial extrusion
through filters with diminishing pore sizes (10 and 8 µm
wide filter membranes) followed by purifications through size
exclusion chromatography, we generated high quantities of
IDEM retaining the distinctive physiochemical and molecular
features of naturally occurring exosomes. As a proof of
principle, the ThP-1 monocytic cell line was chosen to produce
IDEM due to its high proliferation rate and wide applicability
for the development of immunotherapy-based approaches
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(Corradetti, 2016). Furthermore, immune derived platforms
could prove advantageous when applied to an in vivo system.
A systematic comparison between the IDEM formulation with
exosomes extracted from the medium of the same number of
cells through well-established protocols was performed. To assess
their potential use as delivery systems, IDEM were encapsulated
with doxorubicin, as a model chemotherapeutic drug which is
widely used in clinical settings for the treatment of ovarian
cancer, and their therapeutic efficacy evaluated in vitro 2D and
3D ovarian cancer models.
MATERIALS AND METHODS
Cell Culture
Monocytic cell line (ThP-1 cells) was purchased from ATCC.
Cells were grown in Roswell Park Memorial Institute (RPMI)-
1640 medium (ATCC 30-2001TM) containing 10% (v/v) fetal
bovine serum, 100 U/mL penicillin, 0.1 mg/mL streptomycin.
ThP-1 were maintained at a concentration of 1-5 × 105
cells/ml for expansion. Ovarian cancer cells (SKOV-3 cells) were
purchased from Sigma-Aldrich and cultured McCoy’s 5A media
(Gibco) containing 10% (v/v) fetal bovine serum, 100 U/mL
penicillin, 0.1 mg/mL streptomycin. Culture conditions were
established at 37◦C and 5% CO2.
Exosome Production
Immune Derived Exosome Mimetics (IDEM) Synthesis
Immune derived exosome mimetics were synthesized by
optimizing the procedure reported by Goh et al. (2017b), where
cells are passed through porous membranes of decreasing size
in order to be deconstructed and reconstructed consequentially.
Briefly, ThP-1 cells (8.5 × 106) were harvested and washed
twice in PBS. The PBS-resuspended pellet was then filtered
through 10 µm-filter PierceTM spin cups (ThermoFisher) and
centrifuged at 14,000 × g for 10 min at 4◦C. The pelleted
flow-through was resuspended in PBS and the same process
repeated. Consequently, the pellet was passed through 8 µm
filters (Merck-Millipore) with the same centrifuge settings as
before. The pellet was finally resuspended in 150 µL of 0.22 µm-
filtered PBS and run through G-50 Sephadex high capacity
spin columns (SigmaAldrich) for further purification of the
solution. This solution was stored at −80◦C or used for
downstream applications.
Exosomes Extraction and Purification
ThP-1 cells (8.5 × 106) were incubated overnight in 15ml
RPMI-1640 media supplemented with Exo-Free FBS (FisherSci).
Media was then collected and processed through a series of
centrifugations to remove the cellular component (500 × g for
5 min) and any debris (2000 × g for 30 min). The remaining
supernatant was passed through 0.22 µm PES membrane filter
(CellTreat) and then concentrated using 10 KDa Amicon ultra
centrifugal filters (Millipore). Total exosome isolation reagent
(TEIR, Invitrogen) was then added in a 1:1 ratio to the volume
obtained after the Amicon-based concentration process. The
solution was mixed by vortexing for 30 s and incubated overnight
at 4◦C. The next day, the sample was centrifuge at 10,000 × g
for 1 h at 4◦C. The concentrated solution was centrifuged at
10,000 × g for 1 h at 4◦C, and the pellet was resuspended in
0.22 µm filtered PBS. This solution was stored at −80◦C or used
for downstream applications.
Exosomes and IDEM Characterization
Nanoparticles Tracking Analysis (NTA)
Exosome and IDEM samples were analyzed according to the
MISEV2018 Minimal information for studies of extracellular
vesicles (Théry et al., 2018). The NS300 Nanosight System
(Malvern) was used to determine size and concentration. A 100X
dilution in PBS was prepared for each sample. Briefly, five
videos of 60 s each were recorded for each sample, and the
threshold was kept constant at 5. All the experiments were
performed using different batches of EXO/IDEM, and statistical
analysis was based on at least 3 biological replicates. Size
and concentration measurements were done using 11 different
batches of EXO and IDEM.
Evaluation of Exosome-Associated Markers
CD63 quantitation was performed using the antibody-based
ExoELISA-ULTRA Complete Kit (SystemBio) following the
manufacturer’s indications. Briefly, EXO and IDEM were loaded
on a 96-well plate provided by the company and the CD63
positive particle number was quantified against a pre-set
exosomes standard curve. The number of CD63+ particles
obtained was then compared to the total amount of particles
(quantified by NTA) to gather the amount of CD63+ particles
out of the total (Kim et al., 2019). The percentage of EXO
and IDEM presenting the exosomal surface markers CD81 was
determined by flow cytometry. EXO and IDEM were conjugated
with Aldehyde/Sulfate Latex Beads (ThermoFisher). Briefly, 5 ml
stock beads were incubated with 1 × 109 EXO or IDEM for
15 min at room temperature (RT). Consequently, PBS was added
to 1 ml final volume, and the samples were incubated overnight
at RT under shaking. A 100 mM glycine solution was then added
to saturate unbound beads and incubated for 30 min at RT
before centrifugation for 5min at 4000 rpm occurred. Samples
were incubated for 30 min with APC-conjugated antibody for
CD81 (Biolegend). The BD LSR FortessaTM flow cytometer
was employed for samples analysis. 10,000 events per sample
were acquired, and the FCS/SSC parameters were used to gate
nanoparticle-bound beads which have a 4 µm diameter. Data
were analyzed with the FlowJo software (BD).
Scanning Electron Microscope
To analyze IDEM and EXO by Scanning Electron Microscope
(SEM) 50 µL of each sample were placed in 60 × 15 mm petri
dishes and incubated overnight at 4◦C. 2.5% glutaraldehyde was
subsequently added to each sample for 10 min at 4◦C. Samples
were then washed with ethanol at increasing percentages (30–50–
70–90–100%, respectively) for 5 min each at RT. Lastly, samples
were immersed in 50% butanol for 5 min. A 2 × 2 cm Petri
dish piece was mounted with double side carbon tape (Ted Pella
Inc., United States) on an aluminum SEM stub (Ted Pella Inc.,
United States). A 7 nm Iridium film was added to the sample to
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enhance image contrast. A Nava Nano SEM 230 (Thermal Fisher,
United States) was used to image samples. All SEM experiments
were performed at RT (22◦C) and under a high vacuum range
(5 × 10−6 to 2 × 10−6 Torr). The accelerator voltage was set at
5–7 kV for imaging. The electron beam spot-size was set at 3 nm
and the working distance was 5 mm.
Atomic Force Microscopy
Atomic Force Microscope (AFM) Bruker BioScope Catalyst
(Bruker Instruments, Santa Barbara, CA, United States) was
used, and Bruker MLCT-E cantilevers were used to perform
the analysis, with a nominal spring constant of 0.1 N/m. Each
cantilever was calibrated for spring constant determination on a
clean glass slide prior to each measurement. All imaging was done
in PeakForce Tapping, with a scan rate of 1 Hz and a force of 200
pN and scans ranged from 25 to 0.5 µm2. Each high-resolution
image contained one or few exosomes at the center of which a
force curve was taken, with a ramp force of 150 pN (for elastic
modulus calculation) and of 2 nN (for adhesion measurement),
a ramp rate of 1 Hz and a ramp size of 150 nm. 10 ThP-1 and
25 semisynthetic exosomes were considered. Elastic modulus was
obtained using the fitting modulus in the Nanoscope Analysis
software v1.50 on the approach curve of each force curve and





In Equation 1, F is the force applied, E is the Young’s modulus
(fit parameter), υ is the Poisson ratio (0.5), R the radius of
the indenter (20 nm), δ is the indentation depth and α is
the half-angle of the indenter (18◦). For adhesion evaluation,
the percentage of force curves that showed an adhesion event
was considered. Data was then analyzed and plotted using
Mathematica 12.0. Samples were prepared as follows. Briefly,
60 µl of 0.1% of APTES solution was deposited on freshly cleaved
mica flakes (1 µm2), left for 30 min, rinsed with 5 mL of MilliQ
water and dried with N2. Then 100 µl of EXO/IDEM solution
was deposited on the substrate for 2 h, mica was rinsed with 2 mL
of PBS and analyzed with AFM in PBS solution.
Western Blot
After exosomes and IDEM preparation, proteins were extracted
in 80 µL M-PER lysis buffer (ThermoFisher) and quantified
against a BSA standard curve using the PierceTM BCA Protein
Assay Kit (ThermoFisher). Consequently, 20 µg of proteins
were run through a Mini Protean Gel (Bio-Rad) and transferred
onto a PVDF membrane using a semi-wet transferring system
(Bio-Rad). Membranes were then incubated for 1 h in blocking
solution (BSA 5% in TBS-T solution, ThermoFisher), followed
by incubation over night at 4◦C in anti-CD63 rabbit primary
antibody with a 1:1000 dilution (Abcam). The next day,
membranes were washed in TBS-T 3 times and then incubated for
1 h at room temperature with the anti-rabbit secondary antibody
in a 1:2000 dilution (ThermoFisher). Membranes were then
developed using a Chemidoc XRS Molecular Imager (Bio-Rad).
Drug Encapsulation and Encapsulation
Efficiency (EE%) Assessment
Efficiently loading of doxorubicin within IDEM and EXO was
achieved through saponin as an encapsulation enhancer. A 0.1%
concentration of saponin was tested. Briefly, both nanoparticle
solutions were mixed with 400 µg/mL of doxorubicin before
adding saponin, and the mixture was incubated for 5 min at
37◦C in agitation at 200 rpm. Consequently, unencapsulated
doxorubicin was removed using an Exosome Spin Column
(Invitrogen). After the loading, the encapsulation efficiency
(EE%) was measured. To this, 0.1% of Triton-X-100 was
added to the samples for 10 min at RT. The concentration of
doxorubicin encapsulated in both IDEM (IDEM-DOXO) and
EXO (EXO-DOXO) was determined by measuring its excitation
and emission values (480 and 610 nm, respectively) against
a set of known standards with a Synergy H4 Hybrid Plate
Reader (Biotek).
Drug Release Profile
To assess the release profile of the nanoparticle formulations,
EXO-DOXO and IDEM-DOXO samples were injected in two
Snakeskin Dialysis Membranes (10,000 MWCO) that were then
immersed in a beaker with 20 mL PBS heated at 37◦C. At
different time points, 1 mL of PBS was taken from each beaker
for measurement and replaced with 1 mL of fresh 37◦C-heated
PBS for up to 96 h. The doxorubicin fluorescent signal was then
read with a plate reader (Biotek) and compared to a doxorubicin
standard curve. The cumulative drug release was calculated




(Cn · V–Cn−1 · v)
m0
· 100
Where t is the number of time points, Cn is the concentration
of doxorubicin at time t, V the total volume of liquid (in our
case 20 mL), Cn−1concentration of doxorubicin at time t-1, v
non-withdrawn volume (in our case 19 mL), m0 the mass of
doxorubicin in the nanoparticles.
IDEM- and EXO-DOXO Uptake by
Ovarian Cancer Cells
Confocal Microscopy
To assess the IDEM- and EXO-mediated uptake of doxorubicin
by ovarian cancer cells, 1 × 104 SKOV3 cells were seeded in 8-
well of chamber glass slide and cultured overnight. The next day,
1 and 3 µg/mL doses of EXO-DOXO and IDEM-DOXO were
added and left for up to 12 h. At 3 different time points (2, 4,
12 h) cells were washed twice in pre-warmed PBS at pH 7.4, fixed
in 4% paraformaldehyde for 10 min at RT and permeabilized
in 0.1% Triton X-100 in PBS for 5 min. After washing in
PBS twice, cells were stained with phalloidin Alexa-Fluor 488,
diluted 1:200 in PBS, and incubated for 20 min at RT before
staining with DAPI Prolong anti-fade mountant (Invitrogen)
occurred. Samples were imaged with Fluoview TM3000 confocal
microscope (Olympus).
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Flow Cytometry
In order to quantify the percentage of cells containing
doxorubicin, 1 × 105 SKOV-3 cells were seeded in 12 multi-well
plates and cultured overnight. The next day, 1 and 3 µg/mL doses
of EXO-DOXO and IDEM-DOXO were added to the cells and
incubated for 12 h. A free DOXO formulation was added as a
positive control at a 10 µg/mL concentration. At three different
time points (2, 4, 12 h) cells were detached and analyzed for
the doxorubicin signal expression at the excitation of 480 nm
and emission at 590 nm (corresponding to the PerCP-Cy5.5
channel). 10,000 events per sample were acquired with a BD
LSR Fortessa flow cytometer, and the FCS/SSC parameters were
used to gate cells.
Cytotoxic Effect of IDEM- and
EXO-DOXO in 2D
SKOV-3 cells viability in 2D conditions after treatment with
EXO-DOXO and IDEM-DOXO was assessed in vitro using
2 complementary techniques, the Alamar blue assay and the
impedance-based cell index measures, respectively.
Alamar Blue Assay
SKOV-3 cells were seeded at the density of 6000/well on
a 96-well plate and incubated overnight. The following day
they were treated with different concentrations of doxorubicin
encapsulated EXO and IDEM (namely, 1, 3, and 5 µg/mL). Cell
viability was assessed for up to 96 h from the quantification of the
resazurin dye reduction (Ansar Ahmed et al., 1994). Cytotoxicity
was measured by growth inhibition and was plotted as a surviving
percentage over time. At each time point (24, 48, 72, 96 h,
respectively) the absorbance signal of the cells was read at 570 nm
and normalized to the values read at 600 nm with a plate reader
(Biotek). Three biological replicates were performed and the
growth of nanoparticle-treated cells was compared to untreated
controls. Free doxorubicin (at the concentration of 10 µg/mL)
was used as a positive control.
eSight
The xCELLigence RTCA eSight machine (Agilent) was used to
obtain real-time impedance-based measurements of cell adhesion
and proliferation (Chollangi et al., 2018). The user can set
a temporal resolution (how frequent the impedance value is
measured) in which an adimensional value called “cell index” is
measured. SKOV-3 cells were seeded at the density of 6000/well in
a company-provided electronic 96-well microplate and cultured
overnight. The following day, the same doses of nanoparticles
used for the Alamar blue assay were added, and the cell index was
measured for up to 96 h. Data were analyzed with the CELLigence
RTCA Software and plotted as cell index values over time. Right
before adding the treatments, cells in each well were also stained
with 2 µM of the fluorescently labeled Caspase-3 dye (ACEA
Biosciences) which is a marker for early apoptotic events. Four
images per well were taken by the eSight machine at a 10X
magnification every hour using the DAPI channel (429/469 nm),
and all signal-positive cells were counted and plotted by the
RTCA Software as object counts/well over time.
Cytotoxic Effect of IDEM- and
EXO-DOXO in 3D Culture Systems
Spheroids were produced using Ultra Low Attachment (ULA)
plates (Corning). Briefly, SKOV-3 cells were seeded at the density
of 5000 cells/well in a Corning ULA 96-well plate and cultured
overnight. After 24 h, EXO-DOXO and IDEM-DOXO were
added to achieve the concentration of 5 µg/mL of doxorubicin
encapsulated. The cell viability of the spheroids was assessed
using the CellTiter-Glo 3D reagent assay (Promega) at different
time points (24, 48, 72, 96 h respectively) for up to 96 h. Briefly,
the reagent was heated at 22◦C prior to use and added to
experimental wells for 30 min at RT in 1:1 volume ratio. The
plate shaking was essential for a proper spheroids lysis. After
the incubation time, the luminescent signal was read with a
plate reader (Biotek). Free doxorubicin (at the concentration of
10 µg/mL) was used as a positive control. For each time point,
a representative 10X picture of each spheroid was taken with a
IncuCyte Live-Cell analysis system (Essen Bioscience).
Statistical Analysis
For all statistical analysis including size, concentration,
encapsulation efficiency and drug release, cell cytotoxicity
in both 2D and 3D experiments, a two-tailed Student’s t-test was
performed to compare IDEM and EXO. Data with p< 0.05 were
considered significant (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). All
graphs show average values and standard deviation.
RESULTS
EXO and IDEM Synthesis and
Characterization
Exosomes (EXO) and IDEM were obtained as summarized in
Figure 1.
Nanoparticle tracking analysis (NTA) was used to determine
size and concentration of the two formulations. As shown
in Figure 2A, EXO and IDEM presented an average size of
112 ± 14 nm and 177 ± 19 nm, respectively (p < 0.001).
Starting from the same number of ThP-1cells (8.5 × 106), the
optimized procedure allowed for the production of 2.3 × 1010
IDEM compared to 9.4 × 109 EXO obtained following standard
protocols for the isolation of natural exosomes from culture
media. The difference in particle concentration was statistically
significant between the two nanoparticle types, IDEM yielding
a 2.48 times higher concentration than EXO (p < 0.001). The
presence of exosomal markers, the percentage and number
of particles expressing CD63 and CD81 were confirmed by
flow cytometry and ELISA, respectively. Figure 2B shows the
relative number of CD63-positive EXO and IDEM compared
to total particles obtained by NTA analysis. The number of
CD63-positive EXO obtained by ELISA was 5.89 × 109 (which
represents the 62% of the total number) while 1.25 × 1010 of
IDEM were CD63-positive (54%). The presence of the CD81
surface exosomal marker was also confirmed for both particle
types by flow cytometry; 43.5% for IDEM and 40.9% for EXO
(Figure 2C). Western blot analysis was also performed to assess
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 September 2020 | Volume 8 | Article 553576
fcell-08-553576 September 17, 2020 Time: 11:15 # 6
Pisano et al. Immune Derived Exosome Mimetics
FIGURE 1 | Schematics of EXO and IDEM production. (A) Summary of IDEM production through filtered-membrane centrifugation steps. (B) Summary of EXO
extraction from culture media by using the Total Exosome Isolation Reagent (TEIR).
the presence of the TSG-101 marker, a cytosolic protein highly
expressed in exosomes, and confirmed its presence on both EXO
and IDEM (Figure 2E). Characterization data were corroborated
by scanning electron microscopy (Figure 2D) and AFM images
(Figure 2F) that provided morphological information about the
two nanoparticle types. AFM was used to gather insights into the
surface, stiffness and adhesion properties of the nanoparticles.
Tapping mode analysis showed a general deviation from the
globular, near spherical shape expected for exosomes, while
IDEM presented a more uniform, globular shape. The mean
radius was significantly smaller, 95.8 ± 35 nm compared to
129.4 ± 34 nm for EXO and IDEM, respectively (p < 0.05).
EXO had a significantly lower elastic modulus of 0.15 ± 0.1 MPa
compared to IDEM, 0.28 ± 0.14 MPa (p < 0.005). The adhesive
properties of the two nanoparticles were similar, with non-
specific tip-particle adhesion events recorded as 36% for EXO
and 38% for IDEM.
Encapsulation and Drug Release Profile
EXO and IDEM were loaded with doxorubicin using 0.1%
saponin. Figure 3A shows the encapsulation efficiency (EE%)
values normalized to the initial doxorubicin concentration
(400 µg/mL). IDEM showed 28% encapsulation efficiency while
EXO retained 17% of the initial administered drug. After
assessing drug encapsulation, the cumulative drug release from
both EXO and IDEM was determined. Figure 3B shows
the percentage of drug released over a 96-h window. Both
nanoparticle formulations showed a pronounced burst release
that reached a plateau after about 12 h. IDEM proved to
release 60% of drug after 12 h, whereas EXO 40% of the
encapsulated amount.
Nanoparticles Effect on the Proliferation
and Early Apoptosis of Ovarian Cancer
Cells
Cytotoxic effects on ovarian cancer cells (SKOV-3) mediated
by IDEM and EXO loaded with doxorubicin was evaluated
using Alamar blue. Three increasing concentrations (1, 3, and
5 µg/mL) of doxo-encapsulated IDEM (IDEM-DOXO) and
EXO (EXO-DOXO) were added to SKOV-3 cell culture media.
Free doxorubicin (DOXO, 10 µg/mL) was used as a positive
control. This dose was identified as the lowest and most cytotoxic
among different concentrations of doxorubicin tested on cell
viability (data now shown). Figure 4A shows a significant effect
of IDEM-DOXO on SKOV-3 cells, with a 25% reduction in
cell viability at 24 h following the treatment at the lowest
treatment dose (1 µg/mL). Viability decreased further to 70,
75, and 80% at 48, 72, and 96 h respectively. EXO-DOXO at
a 1 µg/mL concentration showed a statistically more enhanced
effect compared to IDEM, again being more cytotoxic than
free DOXO at 24 h (p < 0.05). Increasing the dose of IDEM
to 3 µg/mL resulted in an even more pronounced cytotoxic
effect than free DOXO (Figure 4B), with a 50% reduction in
cell viability occurring at 24 h (p < 0.05). This cytotoxic effect
further increased to 85% reduction in cell viability after 72 h. In
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FIGURE 2 | EXO and IDEM characterization panel. (A) Size (nm) and concentration (particle/ml) values for EXO (in red) and IDEM (in blue) obtained by NTA (n = 11).
Statistically significant differences (p*** < 0.001) were observed between the two particle types formulations. In particular IDEM were 2.48 times more concentrated
than exosomes. (B) Number of CD63-positive EXO and IDEM as measured by ELISA (p* < 0.05). (C) Flow cytometric analysis showing EXO and IDEM stained with
a APC-CD81 antibody. Results show the positive signal compared to unstained exosomes. (D) Scanning electron microscope (SEM) images show rounded particles
phenotypes. (E) Western blot analysis of TSG-101 shows the exosomal marker presence on both EXO and IDEM. (F) Topography and Elastic Modulus of EXO and
IDEM. (Left) A representative AFM image of each formulation. (Middle) Boxplot data for diameters size for EXO and IDEM. Mean EXO value: 96 ± 35 nm. Mean IDEM
value: 129 ± 34 nm. (Right) Boxplot data for Elastic Modulus for EXO and IDEM. Mean EXO value: 0.15 ± 0.10 MPa. Mean IDEM value: 0.28 ± 0.14 MPa
(p* < 0.05).
comparison, the EXO-DOXO treatment brought to a reduction
in viability in a faster fashion, reaching more than 90% cell death
at 96 h (p< 0.05).
Treatments with empty nanoparticles confirmed the cytotoxic
effect was mediated by the encapsulated doxorubicin, and
exclude an inherent nanoparticle effect (data shown in
Supplementary Figure S1A).
To substantiate the Alamar blue assay data, the efficacy of
IDEM-DOXO on cell adhesion and proliferation was also tested
by measuring impedance changes due to cell death resulting
in cell detachment from culture plates (xCELLigence eSight).
Figure 4C shows the effect of 1 µg/mL of IDEM-DOXO on the
cell index of SKOV-3 cells, which represents a non-dimensional
value directly correlated to cell proliferation. The IDEM-DOXO
treatment showed a peak in cell index (=6) in the 40–50 h time
window, followed by a marked reduction in line with the cell
index values of free DOXO and EXO-DOXO. After 110 h, the
cell index of all three treatments was less than 1, indicating
an almost complete decrease in cell viability. A similar trend
was observed when IDEM-DOXO were tested at a 3 µg/mL
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FIGURE 3 | Encapsulation efficiency (EE%) and cumulative drug release profile. (A) EE% values obtained from a doxorubicin starting concentration of 400 µg/mL.
IDEM show higher EE% than EXO (p** < 0.01). (B) Drug release profile (%) of doxorubicin from IDEM and EXO over a 96-h period. A burst release was seen for both
formulations for up to 12 h, followed by a plateau reached soon after.
FIGURE 4 | Cell proliferation assessed by Alamar blue and xCELLigence eSight analysis of cell index. (A) Percentage of viable cells following the treatment with
doxorubicin-loaded IDEM (IDEM-DOXO) and EXO (EXO-DOXO) at 1 µg/mL. Alamar blue assay was used to quantify the percentage of viable cells over a 96-h period.
IDEM- and EXO-DOXO are statistically more cytotoxic than the free doxorubicin formulation (10 µg/mL, DOXO) at 48, 72, and 96 h time points (p* < 0.05). A two-tail
T-test was performed to assess for statistical significance compared to free doxorubicin formulation (DOXO, p* < 0.05). (B) Percentage of SKOV-3 viable cells
following the treatment with IDEM-DOXO and EXO-DOXO at 3 µg/mL. EXO-DOXO were more effective than free doxorubicin (DOXO) in causing cell cytotoxicity on
SKOV-3 cells at all time points (p** < 0.01 at 24 and 48 h, p* < 0.05 at 72 and 96 h respectively) while IDEM-DOXO were significantly more effective at 24 and 48 h
time points (p* < 0.05), both formulations reaching more than 50% reduction in viability as soon as 24 h after the beginning of the experiment. (C) Cell index analysis
of 1 µg/mL of IDEM-DOXO and EXO-DOXO over time, showing a marked decrease in cell index compared to untreated control after up to 110 h. (D) Cell index
analysis of 3 µg/mL of IDEM-DOXO and EXO-DOXO have a similar effect to free DOXO in reducing cell proliferation of SKOV-3 cells for a time period of up to 110 h.
concentration (Figure 4D). The cell index reached a peak value
of 7 in the 35–45 h time window, followed by its decrease in
value to 0.26 after 110 h. Free DOXO and EXO-DOXO reached
a cell index value 0.87 and 0.35 after 110 h, respectively. Again,
nanoparticles confirmed that the reduction in proliferation was
caused by the encapsulated doxorubicin only (data shown in
Supplementary Figure S1B).
Apoptosis was also assessed following IDEM-DOXO and
EXO-DOXO treatment using the eSight system by combining
data for expression levels of the apoptotic marker Caspase3 with
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FIGURE 5 | Quantification of early apoptosis. (A) Analysis of Caspase3 positive cells after treatment with 1 µg/mL of IDEM-DOXO and EXO-DOXO over a 110-h
time period. Ten µg/mL of free doxorubicin (DOXO) was used as a positive control. Pictures were taken every hour and analyzed with the RTCA Software.
(B) Analysis of caspase3 positive cells after treatment with 3 µg/mL of IDEM-DOXO and EXO-DOXO, with IDEM being the most effective in causing early apoptotic
events. (C) Representative images that show the signal intensity which is directly correlated to early apoptotic events. It can be noticed how all treatments lead to
marked early apoptotic events when compared to the untreated control. A 10X magnification objective was used for pictures, with a scale bar of 200 µm.
data extrapolated from the proliferation assay, and correlating
the number of Caspase3 positive cells with pro-apoptotic
activity. 1 and 3 µg/mL treatments with IDEM-DOXO yielded
4900 ± 900 and 7230 ± 314 caspase positive cells after 110 h,
respectively, which was higher than the free DOXO and EXO-
DOXO treatments (Figures 5A,B). For EXO-DOXO treatment
2520 ± 1160 and 2790 ± 660 positive cells were identified
after 1 and 3 µg/mL treatments, while free DOXO yielded
1630 ± 670 positive cells. A clear increase in the number of
Caspase-3 positive cells can be seen when comparing both the
untreated and the free DOXO-treated cells with the exosomes
and IDEM treatments (Figure 5C). No apoptotic effect was seen
when empty nanoparticles were tested as controls (data shown in
Supplementary Figure S2).
Doxorubicin Uptake
A 3 µg/mL dose of both exosomes and IDEM was added to
SKOV-3 cells for 2, 4, and 12 h to evaluate DOXO uptake. The
autofluorescent signal intensity of DOXO increasing over time
was inferred from microscopy images (Figure 6A) and quantified
using flow cytometry. Both, IDEM-DOXO and EXO-DOXO
show a similar pattern of incremental uptake by SKOV-3 cells
with slightly less uptake than free doxorubicin (Figure 6B).
Cytotoxic Effect of IDEM on Ovarian
Cancer Cells in 3D
After testing the effect of the nanoparticle treatments in 2D
systems, we evaluated their effect in a more complex spheroid
system which better mimics the in vivo environment. 24 h
post-spheroid formation, cells were treated with 5 µg/mL of
IDEM-DOXO and EXO-DOXO and monitored for up to 96 h.
The presence of doxorubicin, both as a free formulation and
encapsulated in IDEM or EXO, affects the shape and the color of
spheroids causing them to lose integrity and to become darker, as
can be noticed by eye in Figure 7A. These phenotypical changes
might be due to increased levels of necrosis in the spheroids
inner core, as has been extensively reported in literature (Freyer,
1988; Sokolova et al., 2019). These effects were corroborated by
assessing cell viability; IDEM-DOXO particles were as effective
as EXO-DOXO, and both formulations were more cytotoxic than
free doxorubicin in reducing spheroids proliferation by almost
20% after 24 h (p < 0.01 and <0.05, respectively; Figure 7B).
IDEM-DOXO showed the same effect as doxorubicin at 48 and
72 h, but its effects were significantly greater after 96 h (p< 0.05).
Similarly, doxorubicin-loaded exosomes were significantly more
effective than DOXO at 72 and 96 h (p< 0.001).
DISCUSSION
Due to their role in intercellular communication, exosomes are
being increasingly explored as delivery systems for biomedical
purposes. In particular, the organotropism of exosomes toward
tumor sites and metastatic niche makes them ideal candidates
for the development of efficient anticancer therapies targeting
metastatic cancer with reduced side effects. However, the
main drawbacks for the application of naturally occurring
exosomes are the challenges of large-scale production, isolation,
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FIGURE 6 | Doxorubicin uptake analysis. (A) Confocal microscopy images showing an increasing signal associated to free doxorubicin (DOXO, 10 µg/ml),
EXO-DOXO (3 µg/ml), and IDEM-DOXO (3 µg/ml) uptake by SKOV-3 cells overtime (2, 4, 12 h). 40x Magnification, with a 50 µm scale bar. (B) Flow cytometry was
used to quantify the amount of doxorubicin encapsulated at 2, 4, 12 h following cell treatment. The PerCP-Cy5.5 channel was used to detect doxorubicin
autofluorescence signal and was compared to untreated cells to set the unstained signal. Both IDEM-DOXO and EXO-DOXO show increased signal intensity over
time, however, free doxorubicin displays the brightest signal following uptake by SKOV-3 cells.
FIGURE 7 | Effect of EXO and IDEM on 3D ovarian cancer model. (A) Representative images taken at 24, 48, 72, and 96 h following the treatment with 5 µg/mL of
IDEM-DOXO and EXO-DOXO and 10 µg/mL of free doxorubicin (DOXO), while empty EXO and IDEM were used as negative controls (IDEM CTRL and EXO CTRL,
respectively). Untreated cells are included as negative control (CTRL). The effect of doxorubicin is evident in increasing necrosis and reducing spheroids integrity, as
indicated by the red arrows. (B) Percentage of cell viability normalized to the untreated control of all treatments obtained with the CellTiter Glo viability assay.
IDEM-DOXO were significantly more effective than DOXO at 24 and 96 h time points (*p < 0.05) while EXO-DOXO were the most effective at all time points
(***p < 0.001 at 72 and 96 h).
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modification and purification (Ha et al., 2016; Akuma et al.,
2019). Exosome mimetics hold the promise to improve the
delivery of bioactive molecules with therapeutic efficacy,
while achieving scalability and increasing bioavailability
due to their minimal immunogenicity (Antimisiaris et al.,
2018). In this work we propose a system to scale up the
production of exosome mimetics from immune cells. By
subjecting cells to serial extrusion steps through filters
with diminishing pore sizes and by consequently loading
them with a chemotherapeutic agent, we generated high
quantities of exosome-mimetic nanovesicles carrying sheltered
drugs. Compared to standard procedures for the production
of exosomes, our approach allows for a rapid synthesis
and purification, which represents a practical advantage in
terms of production.
Starting from the same number of cells (8.5 million ThP-1
cells), our approach led to a 2.5-fold increase in the number
of IDEM particles obtained, compared to naturally released
exosomes (EXO). Despite the greater average diameter of
IDEM compared to EXO (177 ± 19 nm vs. 112 ± 14 nm,
respectively), IDEM remain within the size-window that is
expected for exosomes (Doyle and Wang, 2019), and retain
the typical molecular and mechanical features of natural
exosomes. IDEM tested positive for the tetraspanins CD81
and CD63, the presence of which has been widely associated
with endosomal-derived exosomes (CD81) (Greening et al.,
2017; Hikita et al., 2018) and have been proved to be
cell-type dependent (CD63) (Kowal et al., 2016). Levels
of CD81 and CD63 found in IDEM were comparable to
those found in exosomes isolated from the media of the
same cell population, confirming their similarity with their
physiological counterparts.
Through SEM and AFM analysis, three-dimensional
morphological images of both particles were generated showing
a spheroidal shape. Size measurements performed by AFM
for both particle types followed the same trend obtained by
NTA, although average particle size was lower when measured
with AFM, and attributed to the different measurement
techniques (Sharma et al., 2010, 2011; Paolini et al., 2016).
Nanomechanical analysis revealed that both particle types
had same adhesive characteristics indicating similar surface
composition (Whitehead et al., 2015).
In contrast, IDEM particles had a greater elastic modulus
indicating an increased stability. A greater elastic modulus has
been as well associated with a better cellular uptake efficiency
(Sun et al., 2015; Wang et al., 2019), although this effect has not
been observed in the present study.
IDEM proved to be an effective drug delivery system
when loaded with the chemotherapeutic agent doxorubicin
which is currently the standard of care approach for the
treatment of metastatic ovarian cancer (Gordon, 2005;
Cronin et al., 2013). Efficient doxorubicin encapsulation
was achieved using saponin treatment yielding 28 and
17% drug encapsulation for IDEM compared to EXO
respectively. This further demonstrates the enhanced
benefits of IDEM over EXO, since the encapsulation
efficiency of doxorubicin does not generally exceed 20% in
exosomes (Gomari et al., 2018; Wei et al., 2019). Moreover,
IDEM released an amount of drug over time up to 20%
greater than exosomes.
Exosomes deploy different characteristics that render them
an attracting system for cancer therapy. For instance, they can
be taken up by acceptor cells (and alter cellular processes),
and can avoid blood clearance by the immune system
(Antimisiaris et al., 2018). These aspects together with the
nanoscopic size are likely to permit their penetration into
tumor bulks or in reaching secondary metastatic sites, which
represent one of the main challenges in ovarian cancer
treatment specifically (Mitra, 2016; Cheng et al., 2017).
IDEMs encompass these exosomes features and provide a
suitable alternative as they are reconfigurable and more
clinically translatable due to their scalability properties. In
order to assess the applicability of IDEM in an ovarian
cancer setting SKOV-3 cells were used to evaluate the
cytotoxic effect of doxorubicin-loaded IDEM. Interestingly,
both IDEM and EXO proved to be more efficient than
the free drug despite DOXO being delivered at a lower
drug concentration, with the EXO-DOXO treatment being
statistically more effective than IDEM-DOXO as well. This
event might be due to different uptake mechanisms of EXO-
DOXO/IDEM-DOXO by SKOV-3 cells compared to the free
Doxorubicin, leading to a more enhanced cytotoxic effect of the
chemotherapeutic agent. Also, as highlighted from the higher
cytotoxic effect of EXO CTRL on SKOV-3 cells compared to
IDEM, we speculate additional exosomal components might
be involved in the effect mediated by EXO which are
not present in IDEM. Moreover, drug efflux pumps which
expel drugs from cells are known to be at the base of
multi-drug resistance (Filipits, 2004). In contrast, liposomal-
based nanoformulations, which have a similar theoretical
composition to EXO and IDEM, have been proven to increase
retention of drug into cells, thus increasing their efficacy
(Patel et al., 2013).
In addition to these findings, IDEM-DOXO effectively
reduced cell proliferation at the concentrations of 1 and 3 µg/ml,
where the cell index analysis revealed two peaks in the 38–
45 h window. This might be explained with an initial cell
bloating, corresponding to increased impedance levels, followed
by cell disruption resulting in cell index decrease. Doxorubicin-
loaded IDEM also induce the highest rates of caspase3-dependent
early apoptotic events in SKOV-3 cells compared to EXO,
allowing us to evaluate the extent and timing of this mechanism.
In the case of our IDEM, this could be an indication of a
better efficacy index. Moreover, the higher apoptosis ratios after
the IDEM-DOXO treatment might be explained with different
uptake rates or possibly differential uptake mechanisms by
SKOV-3 cells, which might lead to a faster activation of the
apoptotic cascade.
In order to gain more information about the behavior of
our platform in more complex systems, the cytotoxic effect
of doxorubicin-loaded IDEM was tested on SKOV-3-generated
spheroids. Data obtained show again a more enhanced activity
when compared to the free doxorubicin formulation. Although
the efficacy of doxorubicin in penetrating spheroid systems
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resembling tumor masses to exert its effect has been widely
established (Sokolova et al., 2019), our results support the
idea that the addition of exosome-like delivery systems can
further improve the chemotherapeutic penetration and, hence,
the efficacy of the therapy.
Overall, we demonstrate the feasibility of our IDEM platform
as an effective alternative to exosomes for the development
of semi-synthetic nanoparticles for ovarian cancer therapeutics.
Compared to EXO, the advantages IDEM offer include the rapid
synthesis and purification, the higher production yields, and
an increased encapsulation efficiency/release, which make them
potential candidates for clinical translation. Moreover, the use
of the ThP-1 monocytic cell line for IDEM production not
only has a practical advantage due to its ease of expansion
in laboratory culture systems, but also proves convenient for
the development of anti-cancer strategies with a potential
application in the more complex environment found in in vivo
settings, where the immune system plays a crucial role. ThP-
1 cells can help investigate the interaction of cancer systems
with different macrophages types (these cells can also be
differentiated in M0/M1/M2 macrophages), allowing us to
further deepen our understanding of the potential of IDEM
derived from different macrophage types to efficiently interact
with OC systems.
Exosomes retain parent cell characteristics in terms of
surface markers, content and cell pathway activation, properties
that assume a pivotal role when related to immune cells,
particularly in terms of tumor recognition to exert an effective
response (Wen et al., 2017). Notably, exosomes derived from
precursor monocyte populations do not exhibit the pro-
active inflammatory properties associated with their “offspring”
macrophages highlighting the importance that the source of
exosomes play in activating or suppressing the immune response
following administration (Rice et al., 2018). As such, the use of
monocyte-derived exosome mimetics combines the advantages of
a biomimetic drug-delivery system with reduced immunogenicity
as they should not induce systemic inflammation following
infusion nor face being rejected by the immune system.
Regardless of the lower in vitro efficacy of IDEM-DOXO
when compared to EXO-DOXO, our exosome mimetics still
outperformed the free drug treatment. Hence, we believe IDEM
will contribute to revolutionizing the treatment of malignancies
for which a semi-synthetic, highly efficient, reproducible, and fast
approach is paramount.
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